US-based Hawthorne Health and Pharmacy Research Organisation RxE2 have partnered to expand patient access to clinical trials in local communities.
Under the partnership, both companies will work to advance community-based clinical trials.
Hawthorne Health specialises in community trial delivery with access to community-based locations, including homes, pharmacies, and patient centres.
On the other hand, RxE2 provides pharmacist-led clinical trial services to make trials a cost-effective reality.
The company collaborates with sponsors and CROs to enhance clinical trial efficiency, providing pharmacists with a single access point for all pharmacy-care services.
The deal combines Hawthorne Health’s GCP-trained nurse network with RxE2’s community pharmacist integration. This creates a network of community-based clinical trial locations.
Sponsors can now reach a broader patient population, simplify trial logistics, and offer flexible, patient-focused trial options in trusted, local settings.
Hawthorne Health CEO Josh Rose said: “Patient access and retention continue to be major challenges in clinical research.
“This partnership enables us to address these issues head-on by meeting patients where they are. Offering flexible trial options, not only boosts participation but also enhances data quality and drives overall study success.”
The partnership combines the strengths of both organisations for more efficiency and scalability across clinical trials.
It will use an integrated approach to expand access to studies. With thousands of locations across all 50 states, it creates a flexible, community-based network.
Additionally, this sets a new industry standard, transforming the future of clinical trial execution, Hawthorne Health said.
RxE2 CEO Gerald Finken said: “By bringing trials directly to patients within their communities, we are not only improving access but also creating a more personal and supportive experience for participants, similar to the care they receive at their local community pharmacy.
“Together, with our synergistic services and AI-enabled technologies, we are setting a new benchmark for inclusivity and effectiveness in clinical trials.”
Hawthorne Health uses technology to prioritise patient access, engagement, and retention, leading to better clinical outcomes.
By offering assessments in home and community settings, the company speeds up the development of new therapies.
The company has over 40 development sponsors, 20,000 study visits, 50,000 assessments, and five successful US Food and Drug Administration (FDA) audits.
In January 2024, Hawthorne Health and Labcorp entered a collaboration to enhance decentralised clinical trials.
